According to reports, JUNSHI BIO (01877) opened nearly 5% higher and, as of the time of posting, was up 4.94% at HKD 28.04 with a trading volume of HKD 6.41 million. Recently, the company announced that its product, the recombinant humanized bispecific antibody against PD-1 and VEGF (code name: JS207), has received approval from the U.S. Food and Drug Administration (FDA) for its clinical trial application comparing JS207 to nab-paclitaxel in an open-label, two-arm, randomized, positive-controlled Phase II/III clinical study for the neoadjuvant treatment of resectable, AGA-negative non-small cell lung cancer patients. JS207 is a self-developed recombinant humanized bispecific antibody targeting PD-1 and VEGF, primarily used for treating advanced malignant tumors. It binds with high affinity to both PD-1 and VEGFA, effectively blocking the interaction between PD-1 and PD-L1/PD-L2, while also inhibiting the binding of VEGF to its receptors. JS207 exhibits both immunotherapy and anti-angiogenesis therapeutic characteristics by neutralizing VEGF, which suppresses the proliferation of vascular endothelial cells, improves the tumor microenvironment, and enhances the infiltration of cytotoxic T lymphocytes in the tumor microenvironment, thus achieving better antitumor activity. As of the announcement date, JS207 has been approved to enter the Phase II/III clinical research phase, with several Phase II clinical studies ongoing, exploring combinations with chemotherapies, monoclonal antibodies, and antibody-drug conjugates (ADC) across various malignancies, including non-small cell lung cancer, colorectal cancer, triple-negative breast cancer, and liver cancer.